Tirzepatide

Fat LossFDA-approved dual incretin agonistEstablished

FDA-approved weekly dual GIP/GLP-1 receptor agonist for type 2 diabetes (Mounjaro) and obesity (Zepbound). Typical titration 2.5→15 mg. Not WADA-prohibited (monitoring).

Calculate Dose

For research use only.

Key Facts

CAS: 2023788-19-2
Molecular Weight (MW): ≈4813 g/mol
Half-life: ~5 days
Unit: mcg
Administration Route: Subcutaneous
Frequency: Once weekly
Last updated: 8/23/2026
Targets: GIP receptorGLP-1 receptor

Overview

FDA-approved weekly dual GIP/GLP-1 receptor agonist for type 2 diabetes (Mounjaro) and obesity (Zepbound). Typical titration 2.5→15 mg. Not WADA-prohibited (monitoring).

Protocol

Dosage Range: 2.5-15 mg weekly (titrated)
Frequency: Once weekly
Cycle: Long-term use as prescribed
Administration Route: Subcutaneous
Reconstitution Guide: Prefilled pen - no reconstitution needed

Science

Mechanism of Action

Imbalanced dual agonist that is more potent at GIPR than GLP-1R, improving glycemia and producing greater mean weight loss than semaglutide in head-to-head obesity trials.

Targets

GIP receptorGLP-1 receptor

Studies

SURPASS-2 vs semaglutide— Journal/year not available
SURMOUNT-1 obesity— Journal/year not available

Benefits

Superior weight loss compared to semaglutide (up to 22.5% body weight)Excellent glycemic control in type 2 diabetesReduced cardiovascular riskImproved blood pressureBetter lipid profile